Clinical Pharmacokinetics of Meloxicam: A Cyclo-Oxygenase-2 Preferential Nonsteroidal Anti-Inflammatory Drug

Authors: Davies N.M.1; Skjodt N.M.2

Source: Clinical Pharmacokinetics, Volume 36, Number 2, February 1999 , pp. 115-126(12)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide] is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class which shows preferential inhibition of cyclo-oxygenase-2.

Meloxicam has a plasma half-life of approximately 20 hours, making it convenient for once-daily administration. Meloxicam is eliminated after biotransformation to 4 pharmacologically inactive metabolites, which are excreted in urine and faeces. Meloxicam and its metabolites bind extensively to plasma albumin. Substantial concentrations of meloxicam are attained in synovial fluid, the proposed site of action in chronic inflammatory arthropathies.

Neither moderate renal nor hepatic insufficiency significantly alter the pharmacokinetics of meloxicam. Dosage adjustment is not required in the elderly. Drug-drug interaction studies are available for some commonly co-prescribed medications. Concentration-dependent therapeutic and toxicological effects have yet to be extensively elucidated for this NSAID.

Keywords: Reviews-on-treatment; Meloxicam, pharmacokinetics; Meloxicam, drug-interactions; Drug-interactions; Nonsteroidal-antiinflammatories, pharmacokinetics; Bioavailability; Clinical-pharmacokinetics; Rheumatic-disorders; Metabolism; Nonsteroidal-antiinflammatories, drug-interactions

Language: English

Document Type: Review article

Affiliations: 1: Department of Pharmaceutics, School of Pharmacy, College of Health Sciences, University of Sydney, Sydney, New South Wales, Australia 2: Respiratory Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada *

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$57.95 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A